Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Recent & Breaking News (OTCQX:RHHBY)

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm

Business Wire June 6, 2017

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Roche Holding AG – RHHBY

Business Wire June 6, 2017

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Roche Holding AG and Encourages Investors with Losses to Contact the Firm

Business Wire June 6, 2017

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Roche Holding AG Investors

Business Wire June 6, 2017

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Roche Holding AG

Business Wire June 5, 2017

COMPANY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Roche Holding AG to Contact the Firm

Business Wire June 5, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Herbalife, Ltd. (HLF)

PR Newswire June 5, 2017

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Roche Holding AG - RHHBY

Business Wire June 5, 2017

Roche receives FDA approval for CMV viral load testing on cobas® 6800/8800 Systems

PR Newswire June 5, 2017

APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer

Business Wire June 5, 2017

Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer

Business Wire June 5, 2017

Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

PR Newswire June 1, 2017

The Current State Of The Breast Cancer Treatment Space

Benzinga.com  May 23, 2017

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis

Business Wire May 22, 2017

The Most Notable Abstracts Released Ahead Of ASCO 2017

Benzinga.com  May 19, 2017

Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire May 11, 2017

Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancer

Business Wire May 10, 2017

Roche's VENTANA PD-L1 (SP263) Assay gains CE label expansion to inform treatment decisions in lung cancer patients being considered for KEYTRUDA (pembrolizumab) immunotherapy

PR Newswire Europe Non Regulatory May 5, 2017

Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinoma

PR Newswire May 2, 2017

FDA clears Roche high-volume immunoassay lab testing solution to support critical medical treatment decisions

PR Newswire May 1, 2017